Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Jose Cruz
Phone: 713.441.4457
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement. < ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Michelle Guthrie
Phone: 713.441.6564
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined. ... Read more >
Status: Open Not Enrolling
Investigator: Kirk Heyne
Study Coordinator: Jose Cruz
Phone: 713.441.4457
This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of t ... Read more >
Status: Open Not Enrolling
Investigator: Rafik Ghobrial
Study Coordinator: Darrel Cleere
Phone: 713.441.6232
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option f ... Read more >
Status: Enrolling
Investigator: Kirk Heyne
Study Coordinator: Pej Hemati
Phone: 713.441.3926
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced uro ... Read more >
